Lynx1 Capital Management LP - Insider Trading & Ownership

Location
151 Calle De San Francisco, Suite 200 Pmb 1237, San Juan, PR
Summary
The estimated value of insider holdings of Lynx1 Capital Management LP is at least $125M dollars as of October 30, 2025. Lynx1 Capital Management LP is the 10%+ Owner of Cullinan Therapeutics, Inc. and owns shares of Cullinan Therapeutics, Inc. (CGEM) stock worth about $75.3M. Lynx1 Capital Management LP is the 10%+ Owner of TScan Therapeutics, Inc. and owns shares of TScan Therapeutics, Inc. (TCRX) stock worth about $39.5M. Lynx1 Capital Management LP is the 10%+ Owner of Neuphoria Therapeutics Inc. and owns shares of Neuphoria Therapeutics Inc. (NEUP) stock worth about $10.4M. Lynx1 Capital Management LP is the 10%+ Owner of Passage BIO, Inc. and owns shares of Passage BIO, Inc. (PASG) stock worth about $195K.
Signature
Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member
All Insider Reports
All Insider Reports

Ownership of Lynx1 Capital Management LP

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CGEM Cullinan Therapeutics, Inc. 10%+ Owner $75.3M +$13.3M +21.5% Oct 28, 2025
TCRX TScan Therapeutics, Inc. 10%+ Owner $39.5M +$33.5M +554% May 19, 2025
NEUP Neuphoria Therapeutics Inc. 10%+ Owner $10.4M Oct 21, 2025
PASG Passage BIO, Inc. 10%+ Owner $195K +$526K Sep 11, 2025

Insider Transactions Reported by Lynx1 Capital Management LP:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.